Company Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States.
It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis.
Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers.
The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
| Country | United States |
| IPO Date | Sep 23, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 239 |
| CEO | Dr. Vladimir Coric M.D. |
Contact Details
Address: 215 Church Street New Haven, Connecticut United States | |
| Website | https://www.biohavenpharma.com |
Stock Details
| Ticker Symbol | BHVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001689813 |
| CUSIP Number | G11196105 |
| ISIN Number | VGG1110E1079 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladimir Coric M.D. | Chairman & Chief Executive Officer |
| Matthew Buten | Chief Financial Officer |
| Warren Volles J.D. | General Counsel & Chief Legal Officer |
| Clifford Bechtold M.S. | President, GM of Biohaven Ireland & Chief Compliance Officer |
| Deb Young | Director of Regulatory Affairs & Operations |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer |
| George C. Clark | Vice President & Chief Accounting Officer |
| Jennifer Porcelli | Vice President of Investor Relations |
| John Tilton | Chief Commercial Officer of Rare Diseases |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2024 | CT ORDER | Filing |
| Oct 03, 2024 | 4 | Filing |
| Oct 03, 2024 | 4 | Filing |
| Oct 02, 2024 | 8-K | Current Report |
| Oct 01, 2024 | 424B5 | Filing |